Surgery, endoscopy or medication, compared on evidence
For forty years the choice was diet or an operation. Now there is a stitch inside the stomach done through the mouth, a balloon, and weekly injections that rival a sleeve. They differ in how much weight goes, how long it stays off and what can go wrong. We put them on the same scale.
Beyond the Knife: Weight Loss Options Ranked
27 minutes. A narrated research briefing from the Bariatric Alt editors, with every source checked.
Read what the episode covers
Obesity Treatment Before GLP-1 Drugs Arrived
For most of medical history, if you were severely obese and wanted to do something serious about it, your options were roughly as follows: eat less, move more, or let a surgeon rearrange your digestive system in a way that would make your high school biology teacher dizzy. That was it. Diet and exercise have been the official recommendation since approximately forever, and they work about as well as you would expect given that 42 percent of Americans are obese right now, today, despite decades of being told to eat a salad. So in practice, for the millions of people with obesity serious enough to be a genuine medical problem, surgery was the only tool that actually moved the needle.
Bariatric surgery has been around in various forms since the 1950s, and by the time the 2020s arrived it had settled into two main procedures. The first is Roux-en-Y gastric bypass, which involves creating a small stomach pouch and rerouting the small intestine so food bypasses the first stretch of the gut entirely. The second is sleeve gastrectomy, which removes roughly 80 percent of the stomach and leaves behind a narrow tube. Sleeve gastrectomy is now the most commonly performed bariatric procedure in the world, which is a sentence that would have baffled every physician alive in 1970. In the United States alone, around 280,000 metabolic and bariatric procedures were performed in 2022. That sounds like a lot until you realize it represents about 1 percent of the people who actually meet the BMI criteria to qualify. One percent. The other 99 percent either could not access surgery, did not want it, could not afford it, or were told by their insurance company that their suffering did not meet the threshold for coverage. The insurance industry has many ways of saying no. That is one of the quieter ones.
Then, over the course of a few years, something changed. A class of drugs called GLP-1 receptor agonists had been working quietly in diabetes treatment for a while, doing modest work lowering blood sugar and producing some incidental weight loss. Researchers noticed the weight loss part and started investigating harder. The results were not modest. Semaglutide, the drug sold as Ozempic for diabetes and Wegovy for obesity, was producing total body weight loss of around 10 to 15 percent in clinical trials. For a 250-pound person, 15 percent is 37 pounds, which is not a rounding error. People who had never been able to lose meaningful weight through any other means were losing it consistently on a weekly injection.
Then tirzepatide arrived and made semaglutide look restrained. Tirzepatide is a dual agonist made by Eli Lilly, hitting both the GLP-1 receptor and the GIP receptor simultaneously, and in the SURMOUNT-1 trial it produced weight loss of up to 22.5 percent of total body weight at the highest dose. More than a third of participants on the 15 milligram dose lost 25 percent or more of their body weight. Those are surgical numbers. For the first time in the history of obesity medicine, an injection was producing results that surgeons previously had to cut someone open to achieve. The medical community's response ranged from excitement to something more like existential confusion, depending on whether your specialty involves a scalpel.
GLP-1 Drugs Force Bariatric Surgery to Justify Itself
This set off a real reckoning. If a weekly shot can get someone to 20 percent weight loss, why would anyone go under general anesthesia? And if surgery is no longer the only route to dramatic weight reduction, what exactly is it still for? A 2026 systematic review pulling together data from over 25,000 patients compared these medications directly against bariatric surgery across every major outcome category and found that surgery still wins. Across all five primary domains measured, surgery outperforms drug treatment. Every single one. So the question is not whether surgery is better on paper. The question is for whom, under what circumstances, and what happens when the drugs stop working. Those are considerably less simple questions, and the answers will occupy the rest of this conversation.
The numbers behind bariatric surgery matter before we start comparing them to anything else, because the comparison only makes sense once you know what surgery actually delivers. And the answer, after decades of follow-up data, is: quite a lot, with some asterisks.
The SLEEVEPASS trial is the gold standard reference here. It is a randomized controlled trial that followed patients for ten years after their procedures, which in surgical research qualifies as practically geological. At the ten-year mark, patients who had sleeve gastrectomy lost a median of 43.5 percent of their excess body weight. That is not a trivial number. Patients who had Roux-en-Y gastric bypass lost 50.7 percent of their excess weight. The difference between those two procedures was 8.4 percentage points, which held up statistically. Bypass wins on raw weight loss, and it has been winning consistently for a decade.
The LABS study, a large multicenter observational cohort in the United States, adds real-world texture to these figures. Seven years after Roux-en-Y gastric bypass, patients had lost a mean of 38.2 kilograms, representing 28.4 percent of their baseline body weight. For a person who weighed 300 pounds going into surgery, that is around 85 pounds still gone seven years later. The adjustable gastric band, which was still being implanted in meaningful numbers when LABS enrolled patients, produced only 14.9 percent total body weight loss at seven years. The band has since fallen so far out of favor it barely registers in current practice, which is medicine's way of retiring a procedure without holding a formal funeral.
Where the two main procedures diverge most sharply is not on the scale. It is in the stomach. Sleeve gastrectomy has a reflux problem. At ten years in SLEEVEPASS, esophagitis was present in 31 percent of sleeve gastrectomy patients. After gastric bypass, that number was 7 percent. Reflux is unpleasant in the short term and creates more serious concerns over a decade, which is one reason surgeons increasingly hesitate before recommending sleeve to patients who already have heartburn. The Oseberg trial reinforced this at five years, showing pathological acid reflux occurred at a rate 51 percentage points higher after sleeve than after bypass. The stomach does not respond well to being compressed into a tube and then expected to act normal.
Bypass Beats Sleeve on Hypertension Remission Rates
Hypertension remission also split along procedure lines. Ten years out in SLEEVEPASS, 24 percent of gastric bypass patients had achieved hypertension remission, versus 8 percent after sleeve gastrectomy. That is a three-to-one ratio on one of the most common and dangerous comorbidities in this patient population.
Neither procedure gets off entirely clean on complications. Sleeve gastrectomy showed lower rates of late major complications compared to bypass in a meta-analysis of nine randomized trials. Gastric bypass produced meaningfully better GERD improvement. The reoperation rates at ten years in SLEEVEPASS were 15.7 percent for sleeve and 18.5 percent for bypass, a difference that did not reach statistical significance. So roughly one in six patients ended up back in the operating room within a decade regardless of which procedure they had originally, which is the number informed consent forms tend to present in a font that requires reading glasses.
Both procedures reduce bone mineral density over time. At ten years, femoral neck bone density fell significantly after both gastric bypass and sleeve gastrectomy, and ten-year fracture risk estimates were elevated across both. This is a known consequence of rapid weight loss and altered nutrient absorption, and it requires long-term supplementation and monitoring that not every patient sustains.
One-anastomosis gastric bypass rounds out the main surgical options. The BARI-10-POL study reported a median 59.2 percent excess weight loss and 22.8 percent total body weight loss across procedures at ten years. It sits in the landscape as a technically simpler bypass variant that some centers have adopted, with outcomes suggesting it can compete with the major procedures over the long haul, though its evidence base is not yet as deeply characterized as the SLEEVEPASS results.
Diabetes is where the surgery-versus-drugs debate gets its sharpest edge. Weight loss is nice. Diabetes remission is a different category of outcome entirely, because diabetes kills people in slow and unpleasant ways that don't show up on a scale.
Start with the Oseberg trial, which ran at a hospital in Tønsberg, Norway, and enrolled 109 patients with both obesity and type 2 diabetes. Half got gastric bypass, half got sleeve gastrectomy. At five years, 63 percent of bypass patients had achieved diabetes remission using the standard HbA1c threshold of under 6.5 percent without medication. In the sleeve group, that number was 30 percent. A 33 percentage point spread between two surgical procedures done on the same population is large enough to drive treatment guidelines through.
Use the stricter threshold and it widens. At HbA1c at or below 6.0 percent, bypass got 50 percent of patients there. Sleeve got 20 percent. Five years after surgery, bypass is delivering roughly double to triple the diabetes remission rate of sleeve gastrectomy depending on which definition you apply. In a condition that requires lifelong medication management, twice the remission rate is not an incremental difference.
Seven-Year Diabetes Remission After Roux-en-Y Bypass
The LABS cohort backs this up with seven years of real-world follow-up. One year after Roux-en-Y bypass, 71.2 percent of patients with pre-operative diabetes were in remission. By year three it was 69.4 percent. Year five, 64.6 percent. Year seven, 60.2 percent. It declines. But 60 percent of patients still in diabetes remission seven years after a single operation is not a result that needs defending. For comparison, adjustable gastric banding achieved 30.7 percent remission at one year and had dropped to 20.3 percent by year seven, which is consistent with its general habit of underperforming every other procedure at every time point you care to measure.
The DIABETCIR trial took 45 patients and followed them to ten years, randomizing them across three procedures including bypass and sleeve. At the decade mark, gastric bypass had kept 53 percent of patients in remission. Sleeve was at 25 percent. T2DM relapse rates across all three procedures ranged from 41.7 to 50 percent — bypass still finishes well ahead on net. The SLEEVEPASS trial at ten years found no statistically significant difference in diabetes remission between the two procedures, 33 percent for bypass versus 26 percent for sleeve. That seems to contradict Oseberg until you notice that SLEEVEPASS was not powered to detect that difference. It enrolled anyone meeting BMI criteria and treated diabetes remission as a secondary outcome. Oseberg enrolled only patients with type 2 diabetes and was built around that question specifically.
The comparison to GLP-1 medications is where definitions start doing heavy lifting. A 2026 systematic review found that surgery achieved T2DM remission in 23 to 70 percent of patients. For incretin-based drug therapies, true off-medication remission was effectively zero. Observational data using looser criteria found 5.8 to 18.3 percent of long-term GLP-1 users achieving something that qualifies as remission under one definition or another. The more relevant point is that any remission achieved on medication ends when the medication does, and these drugs are expensive enough that insurance-driven discontinuation is a regular clinical event rather than an edge case.
Two predictors of long-term diabetes remission after surgery hold up regardless of which procedure you choose. Shorter preoperative duration of diabetes is one. Greater weight loss in the first postoperative year is the other. There is also a weight-independent mechanism specific to bypass: rerouting food past the duodenum triggers early exaggerated GLP-1 secretion, which improves beta cell function through pathways unconnected to how much weight is lost. This is why a Mayo Clinic study on exactly this question — showing that gastric bypass patients maintained diabetes remission even after significant weight regain at rates sleeve gastrectomy patients did not approach — will anchor its own section shortly. The preview is that bypass does not merely make you smaller. It rewires how the gut communicates with the pancreas, and that rewiring has metabolic consequences that persist even when the weight comes back.
Semaglutide STEP Trials Rewrite Obesity Pharmacology
Before we get to that Mayo Clinic rewiring story, we need to spend some time with the drugs, because the drugs have done something that demands attention. Semaglutide at the 2.4 milligram weekly dose produced results across a clinical trial program called STEP that rewrote what anyone thought was pharmacologically possible in obesity medicine.
The STEP program ran trials across different patient populations. STEP 1 enrolled people with obesity but without diabetes. STEP 2 enrolled people with both obesity and type 2 diabetes, a harder population because diabetes disrupts the metabolic machinery that makes weight loss possible. In that trial at week 68, semaglutide 2.4 mg produced a 10.6 percent weight loss on-treatment, compared to 3.1 percent with placebo. The intention-to-treat analysis came in at 9.6 percent versus 3.4 percent for placebo. Nearly 69 percent of patients on semaglutide lost at least 5 percent of their body weight, against 28.5 percent on placebo.
STEP 3 added intensive behavioral therapy to the semaglutide. The combination produced 16.0 percent mean weight loss at week 68, compared to 5.7 percent for placebo plus the same behavioral support. The on-treatment analysis found 17.6 percent for the semaglutide group. Adding structured dietitian counseling and behavioral support to the drug improved outcomes measurably, which will not surprise anyone who has ever been told that weight loss just requires trying harder.
STEP 10 is where the prediabetes argument becomes compelling. The trial enrolled people with obesity and prediabetes, not yet in full diabetes but clearly heading there. At week 52, semaglutide 2.4 mg produced a mean weight loss of 13.9 percent, compared to 2.7 percent with placebo. More importantly for the diabetes angle, 81 percent of participants in the semaglutide group reverted to normal blood glucose levels. On placebo, that number was 14 percent. The odds ratio was 19.8. For a drug that can move 81 percent of a prediabetic population back to normal blood sugar, the argument for early intervention is not subtle.
Here is the part the press release skips. STEP 10 included an off-treatment follow-up period, and the STEP 1 extension data reinforces the same finding: participants who stopped semaglutide regained 11.6 percentage points of body weight within one year of stopping. They had lost around 15 percent and recovered roughly two-thirds of it in 12 months.
This is how the drug works, not a flaw in it. Semaglutide suppresses appetite through the GLP-1 receptor in the brain and gut. Once the signal stops, appetite returns. For patients whose biology drove them toward obesity in the first place, it returns with full force. The drug manages the condition the way antihypertensives manage high blood pressure, and once the medicine stops, the pressure goes back up. The question is not whether semaglutide works. The question is whether a treatment requiring indefinite continuation is structurally comparable to a one-time surgical procedure, and what happens to patients who can no longer afford it or whose insurance decides to stop covering it. That price is roughly thirteen thousand dollars a year in the United States, a number this article will return to.
Semaglutide's GI Side Effects in Real Numbers
The gastrointestinal tolerability numbers deserve a direct look. In STEP 2, about 63 percent of patients on semaglutide 2.4 mg experienced gastrointestinal adverse events. Most were mild to moderate nausea, vomiting, or diarrhea. The drug's safety profile across the STEP trials was among the most favorable of the pharmacotherapies analyzed in recent network meta-analyses. But 63 percent is still 63 percent, and it is the primary reason people stop the drug early.
The honest summary of the STEP program is that semaglutide outperforms every previous non-surgical obesity medication by a substantial margin. For the millions of people who cannot have bariatric surgery, will not, or have no access to it, this drug is a real option. The gap between semaglutide and surgery on raw weight loss is substantial. The gap on diabetes remission is a different matter, and the Mayo Clinic data that follows will explain why surgery holds an advantage that does not disappear even when the weight comes back.
The SURMOUNT-1 dose breakdown is worth laying out precisely, because the spread across doses reveals something the headline number obscures. The 5 milligram dose — the floor of the trial — produced 16 percent mean weight loss. The 10 milligram dose hit 21.4 percent. The 15 milligram dose hit 22.5 percent. What that progression shows is that tirzepatide's lowest dose already beats semaglutide's best result from the STEP trials. The floor of one drug outperforms the ceiling of the other, which is a reasonable summary of where Eli Lilly and Novo Nordisk currently stand relative to each other in the obesity space.
Then SURMOUNT-5 ran the direct comparison: tirzepatide versus semaglutide, head to head, in 751 participants with obesity but without diabetes, over 72 weeks. Tirzepatide at maximum tolerated dose produced 20.2 percent mean weight loss. Semaglutide at maximum dose produced 13.7 percent. That is a 6.5 percentage point gap. Waist circumference dropped 18.4 centimeters with tirzepatide against 13 centimeters with semaglutide. A cardiovascular post-hoc analysis found tirzepatide associated with a 2.4 percent absolute reduction in predicted 10-year cardiovascular disease risk, versus 1.4 percent for semaglutide. These are not identical drugs with different label colors.
An indirect treatment comparison in patients with obesity and type 2 diabetes found tirzepatide 10 milligrams produced 2.57 percent greater weight reduction than semaglutide 2.4 milligrams, and the 15 milligram dose produced 4.79 percent more. HbA1c fell 0.47 percent further with tirzepatide 10 milligrams and 0.56 percent further with the 15 milligram dose, both statistically significant. In Chinese adults enrolled in SURMOUNT-CN, tirzepatide 15 milligrams produced 17.5 percent weight loss at 52 weeks. The results hold across populations in a way that suggests this is not a drug whose efficacy is contingent on which continent the trial happened to run on.
Tirzepatide Weight Loss Matches Sleeve Gastrectomy Benchmarks
A network meta-analysis of 23 randomized controlled trials then attempted the uncomfortable comparison: tirzepatide at 10 or 15 milligrams against sleeve gastrectomy benchmarks. It found tirzepatide produced 21.3 percent total body weight loss — statistically equivalent to sleeve gastrectomy's 21.1 percent, with overlapping confidence intervals. The surgical community's counterargument is defensible: drug trial time horizons and patient populations are not cleanly matched to surgical series, and the larger 2026 systematic review found surgery outperforming pharmacotherapy across all five primary outcome domains. The equivalence finding comes from a pre-registered analysis, not a press release, and what it does not answer is whether weight loss at 72 weeks means the same thing as weight loss at ten years, which it probably does not, though nobody has actually run that comparison yet.
The withdrawal data provides the necessary frame. SURMOUNT-4 found that participants who stopped tirzepatide regained 14 percent of their body weight in 52 weeks. One year without the drug reversed a substantial share of what the drug had achieved. The drug manages the condition. Remove the management, the condition recovers. This is the same structural problem semaglutide has, played out at a higher starting altitude. You fall further when you stop a more effective drug, which is not a design flaw so much as an arithmetic fact.
The prediabetes numbers go somewhere more interesting. In SURMOUNT-1's 176-week extension, participants with prediabetes were followed for more than three years. Only 1.3 percent of tirzepatide-treated participants developed type 2 diabetes, against 13.3 percent on placebo. The hazard ratio was 0.07. Even in a 17-week off-treatment follow-up, only 2.4 percent of former tirzepatide users had developed diabetes versus 13.7 percent of former placebo participants. A drug that produces a 93 percent reduction in diabetes progression relative to placebo, and retains a measurable protective effect after stopping, is doing something beyond appetite suppression. How durable that protection proves at the ten-year mark is a question the trials have simply not run long enough to answer. Gastrointestinal adverse events were the most common side effect, mostly mild to moderate, concentrated in the first 20 weeks of dose escalation.
Tirzepatide is the most potent approved anti-obesity medication in existence. It outperforms semaglutide across every head-to-head comparison, sits adjacent to sleeve gastrectomy benchmarks in at least one major analysis, and delivers compelling prediabetes prevention data. The terms remain: indefinite treatment required, meaningful regain on stopping, and a list price in the United States that makes it transformative medicine for people with robust insurance coverage and a largely theoretical option for everyone else. Surgery has a different cost structure and does something fundamentally different in the body — particularly to the relationship between weight and blood sugar, even after the weight returns. That is where this article ends up.
Endoscopic Sleeve Gastroplasty as a Surgical Alternative
So where does that leave the person who wants more than a diet plan but less than general anesthesia and a rerouted digestive system? There is a third option that got its first real randomized trial evidence in 2022.
Endoscopic sleeve gastroplasty, ESG, threads an endoscopic suturing device down the throat and stitches the stomach into a narrow tube, reducing it to roughly 30 percent of its original volume. No incision. No resection. The native anatomy stays intact and can be converted to surgical sleeve gastrectomy if the results disappoint. Recovery takes two to three days instead of two to six weeks. In a Lebanese head-to-head comparison with surgical sleeve gastrectomy, mean hospital stay after ESG was 9 hours versus 28 hours after the operation, which is either a medical advance or a commentary on how much we enjoy staying in hospitals.
The MERIT trial is where the real evidence lives. Nine US centers enrolled 209 adults with class 1 or class 2 obesity and randomized them to ESG or a lifestyle modification control arm in a 1.5-to-1 ratio. The control arm received a low-calorie diet combined with physical activity guidance, which is the official medical recommendation for obesity and produced 0.8 percent total body weight loss at 52 weeks. The ESG group lost 13.6 percent. Excess weight loss was 49.2 percent in the ESG arm against 3.2 percent in controls. At the threshold of 25 percent excess weight loss, 77 percent of ESG participants got there versus 12 percent of controls. At 104 weeks, 68 percent of ESG participants were still holding above that mark.
The metabolic picture has a genuine contradiction in it and papering over it would be irresponsible. MERIT found that 80 percent of ESG participants improved in at least one metabolic comorbidity at 52 weeks, while in the control arm, 50 percent worsened. An MBSAQIP real-world database analysis of over 500,000 patients found no clinically meaningful metabolic comorbidity improvement in ESG patients at six months. These two datasets do not resolve into each other cleanly. The most defensible reading is that ESG produces metabolic benefits under controlled trial conditions that are harder to reproduce in unselected real-world populations, which is a sentence that applies to almost every medical intervention and explains why randomized trials exist in the first place.
The physiologic mechanism behind the weight loss is concrete. ESG roughly doubles gastric half-emptying time, from 87 minutes at baseline to 171 minutes at three months post-procedure. It raises fasting GLP-1 by 51 percent and PYY by 6.3 percent at 12 months. The stomach that has been sewn into a tube signals differently to the rest of the body than the one that went in.
Six-year cohort data from 1,377 patients places total body weight loss at 21.2 percent at one year, declining to 14.4 percent at six years. That drop deserves honesty in patient counseling. Comorbidity outcomes at six years include 51.2 percent resolution or improvement of type 2 diabetes, 65.8 percent for hypertension, 73.6 percent for dyslipidemia, and 89.9 percent improvement in sleep apnea. Revision procedures were needed in 5.7 percent of patients. There were no deaths across the cohort. Serious adverse events in the MERIT safety population ran at 2 percent, three events in 131 participants, none requiring surgery or intensive care admission. Surgical sleeve gastrectomy runs 5 to 10 percent for serious adverse events by comparison. The MERIT trial was co-funded by Apollo Endosurgery, which manufactured the suturing system used in every ESG procedure the trial performed, and that funding relationship belongs in the same breath as those safety numbers.
Comparing Costs and Diabetes Predictions Across All Options
A cost-effectiveness analysis placed ESG at $23,432 per quality-adjusted life year gained against lifestyle modification alone. Semaglutide runs roughly thirteen thousand dollars a year and requires indefinite continuation. Bariatric surgery is a one-time cost. ESG sits between them on both axes.
For patients trying to predict whether ESG will work for their diabetes specifically, the Individualized Metabolic Surgery score, a validated tool originally built for bariatric procedures, demonstrated an AUC of 0.85 when applied to ESG outcomes. That is legitimately useful predictive performance for a tool working outside its original population.
The obesity treatment landscape in 2026 is not a binary choice between dieting and an operating room. Gastric bypass remains the most durable intervention for severe obesity and type 2 diabetes, particularly in patients with longer disease duration or prior insulin dependence, because it rewires gut-to-pancreas signaling in ways that persist even when the weight comes back. Tirzepatide closes most of the weight loss gap for patients who can afford to sustain it indefinitely, at a price that functions as an access barrier for a substantial share of the people who need it most. ESG is a real, evidence-supported option with a specific risk-benefit profile that fits patients for whom surgery is too much and a weekly injection for the rest of their lives is too uncertain.
The 99 percent of medically eligible patients currently not receiving bariatric surgery have more options than they had five years ago. Whether those options reach them is, as ever, a question that has nothing to do with the clinical evidence and everything to do with what the insurance company decides to cover this year.
Start here
-
Alternatives to Bariatric Surgery, Ranked by Evidence
A clause-by-clause reading of what the evidence says about alternatives to bariatric surgery: GLP-1 drugs, endoscopic sleeves and balloons, and how each ranks.
-
What Is Bariatric Surgery, and How Does It Actually Work?
What is bariatric surgery? A plain look at the operations, how gut hormones and bile acids drive results, and what the data say about weight loss and diabetes.
-
The Gastric Sleeve: The World's Most Common Weight-Loss Operation
A gastric sleeve is the most common weight-loss operation, yet up to half of patients may need conversion. See the weight loss, reflux, and drug comparisons.
Everything else we have written
- Weight-Loss Surgery and Medication for Teenagers
Bariatric surgery for teens: the adult evidence says diabetes duration, not age, predicted relapse, and the teen-specific data are missing. Here is what that means.
- Bariatric Surgery Cost vs a Lifetime of Medication
Bariatric surgery cost has no sticker price in this research; it shows one $23,432 per QALY figure and how surgery and drug bills differ over time.
- Who Still Does Best With Surgery in the GLP-1 Era?
Who qualifies for bariatric surgery is set by society guidelines, but the evidence shows who does best: earlier diabetes, bypass over sleeve, and what drugs change.
- Bariatric Surgery Twenty Years Later: The Swedish Obese Subjects Study
Bariatric surgery long term: what studies of 10 to 20 years show about weight held, diabetes remission, second operations and late bone and skin problems.
- Endoscopic Revision After Bypass: TORe and Friends
The tore procedure (TORe) sews a stretched gastric bypass outlet smaller through the mouth. Learn what it is, why revisions happen, and what data is missing.
- GLP-1 Drugs After Bariatric Surgery
Ozempic after gastric sleeve: a 4,901-patient study found 13.7% weight loss at 3 years with a GLP-1 drug versus 26.1% after conversion to bypass.
- Weight Regain After Bariatric Surgery: How Common, and Why
Weight regain after gastric sleeve is common, but the rate depends on the definition used. See how studies measure it, the revision numbers, and what follows.
- Duodenal Resurfacing, Liners and the Next Endoscopic Devices
Looking up endobarrier? Learn what the duodenal bypass reasoning behind liner devices rests on, and what current evidence on endoscopic therapies does and does not cover.
- Non-Surgical Weight Loss Options That Have Real Trials Behind Them
Non surgical weight loss compared by tier: lifestyle programs, medications and endoscopic procedures, with trial results from MERIT, STEP 3 and SURMOUNT-1.
- The Gastric Balloon: Six Months of Help, Then What?
A gastric balloon helps while it is in the stomach and fades after removal. See how Orbera, Spatz3 and ESG rank in a network meta-analysis of randomized trials.
- ESG vs Gastric Sleeve: Smaller Procedure, Smaller Result?
ESG vs gastric sleeve compared on weight loss, recovery time, reflux, revisions and cost, and why no large head-to-head randomized trial exists yet.
- Endoscopic Sleeve Gastroplasty and the MERIT Trial
Endoscopic sleeve gastroplasty reshapes the stomach with stitches through the mouth. See what the MERIT trial found at one and two years, and what 'durable' means.
- Diabetes Remission: Surgery vs GLP-1 Drugs
Bariatric surgery diabetes remission runs from 23% to over 70% while GLP-1 drugs score near zero. Here is how the definition of remission shapes those numbers.
- Gastric Sleeve vs Ozempic: Comparing the Numbers Fairly
Gastric sleeve vs ozempic: a network meta-analysis puts tirzepatide and the sleeve 0.2 points apart, but the drug data stops near 72 weeks and the sleeve has ten years.
- Whatever Happened to the Lap-Band?
What long-term data show about the lap band: weaker diabetes remission than gastric bypass, and a Polish study where every band patient followed needed revision.
- Duodenal Switch and SADI-S: The Strongest Operations
How the duodenal switch and SADI-S work, how much weight they take off, what malabsorption costs, and who the evidence says should get them.
- Roux-en-Y Gastric Bypass: The Old Standard Still Holding On
A roux-en-y gastric bypass beat the sleeve on diabetes remission, weight loss and reflux in the Oseberg trial, but cost more low blood sugar. Here is the evidence.
| Option | Weight lost after one year | Weight lost after five years |
|---|---|---|
| Gastric bypass | About 31 percent | About 26 percent |
| Gastric sleeve | About 25 percent | About 19 percent |
| Endoscopic sleeve | 13.6 percent | Still being measured in long trials |
The full chart adds gastric balloons and the GLP-1 drugs, with diabetes remission, durability, typical cost and who each option suits best, on one printable page.
Surgery, Endoscopy or Medication: The Side-by-Side Chart
Sleeve, bypass, endoscopic sleeve, balloon and GLP-1 medication compared on the published evidence: average weight loss, diabetes remission, durability, typical cost and who each suits best, on one printable chart.